Heat will present at the inaugural Emerging Growth Virtual Conference being held March 17 – March 19, presented by Maxim Group LLC and hosted by M-Vest. For more details, click here: http://bit.ly/ 2N3vckE
Heat's positive #ClinicalTrial survival data in non-small cell #LungCancer, with a median overall survival of 24.6 months using our cell-based therapy and Bristol Myers Squibb's Opdivo in checkpoint inhibitor-naive patients, were recently highlighted on Raleigh's CBS station WNCN and in pharmaphorum...
Growing evidence continues to suggest the importance of #TCell immunity to protect against evolving #COVID19 mutations. That’s why we believe our T cell COVID-19 vaccine could be important as new variants emerge. https:// go.nature.com/ 3u3gB9p
Heat's Chief Medical Advisor Dr. George Peoples discusses our newly-released HS-110 data in non-small cell #LungCancer with BioWorld's Michael Fitzhugh. Read the article here: http://bit.ly/ 3jxoizX
We're thrilled to announce positive interim Ph. 2 #data in advanced non-small cell #LungCancer #NSCLC, w/ median ov… https://t.co/2ESfTqVOCe
Proud to announce that we have initiated the manufacturing process for our differentiated ZVX-60 #COVID19 vaccine w… https://t.co/MlMpgWDwsr
CEO @jeffwolfheatbio shares his predictions for trending biotech themes in the coming year with @biospace: https://t.co/CWjuRtXwc7
CEO @jeffwolfheatbio highlights the need for a T-cell activating #COVID #vaccine that can provide long-term protect… https://t.co/QNzRWUG8um
We have completed development of our #COVID19 vaccine cell line, for use as a standalone vaccine, or in combination… https://t.co/JJA0Wt2472
CEO @jeffwolfheatbio stresses the importance of #COVID19 #vaccines that elicit T cell-mediated immune responses to… https://t.co/EI6mAagBHp
Similar Businesses
